Name of the Project
Aspen Pharmacare high-containment facility.
Location
Port Elizabeth, Eastern Cape, South Africa.
Client
Aspen Pharmacare, a subsidiary of Aspen Group.
Project Description
The 23 000 m2 production facility is one of six production facilities at Aspen’s flagship pharmaceuticals manufacturing site, in Port Elizabeth.
At full capacity, the high containment facility is expected to produce about 3.6-billion tablets a year and package about three-million bottles a month.
Initial production in this facility is planned for Alkeran, Leukeran and Purinethol, which are used to treat late-stage cancers; Imuran, which is used in the prevention of organ tissue rejection in liver and kidney transplants, as well as treatment of certain autoimmune diseases; and Benztropine, which is used in the treatment of Parkinson’s disease.
Potential Job Creation
The high containment facility, together with the new sterile facility being built at the same site, will provide about 500 additional jobs.
Value
R1-billion.
Duration
The facility was opened on May 7, 2018.
Latest Developments
None stated.
Key Contracts and Suppliers
None stated.
On Budget and on Time?
Not stated.
Contact Details for Project Information
Aspen Group communications manager Shauneen Beukes, tel +27 82 389 8900.